Objective Prospectively planned pooled analysis evaluating efficacy and tolerability of acute quetiapine XR monotherapy in generalised
- Study Author(s):
- Stein, D. J., Bandelow, B., Merideth, C., Olausson, B., Szamosi, J., & Eriksson, H
- Journal Name:
- Human Psychopharmacology: Clinical and Experimental
- Publication Date:
Methods Data from three 10-week, randomised, double-blind, placebo-controlled studies of similar design were analysed.
Results At Week 8, Hamilton Anxiety Rating Scale (HAM-A) total score significantly improved with quetiapine XR: least squares means
change 13.31, p<0.001 (50 mg/day, n = 452), 14.39, p<0.001 (150 mg/day, n = 673) and 12.50, p<0.05 (300 mg/day, n = 444) versus
11.30 placebo; significant (p<0.001, n = 665) improvements versus placebo were observed with each dose at Week 1. Significant
improvements versus placebo at Week 8 are as follows: HAM-A psychic symptom subscale, Montgomery-Åsberg Depression Rating Scale
total, Pittsburgh Sleep Quality Index global scores for all quetiapine XR doses; HAM-A response and remission rates, HAM-A somatic
symptom subscale score, Clinical Global Impression-Severity of Illness total score, % patients with Clinical Global Impression-Improvement
score ≤2 with quetiapine XR 50 and 150 mg/day; and Quality of Life Enjoyment and Satisfaction Questionnaire short form % maximum total
score with quetiapine XR 150 mg/day. In the quetiapine XR 50, 150 and 300 mg/day and placebo groups, 13.2%, 16.5%, 24.0% and 5.4% of
patients discontinued because of an adverse event, and 1.9%, 1.4%, 3.7% and 1.8% of patients experienced clinically significant changes in
glucose. The most common adverse events with quetiapine XR included dry mouth, somnolence, sedation and constipation.
Conclusion Quetiapine XR monotherapy reduced the symptoms of generalised anxiety disorder, with improvement from Week 1. Adverse
events were consistent with the known tolerability profile of quetiapine. Copyright © 2011 John Wiley & Sons, Ltd.